Recently Added

  • ABECMA® (idecabtagene vicleucel)


    BMS

    Abecma (Idecabtagene Vicleucel) Is A B-Cell Maturation Antigen (Bcma)-Directed Genetically Modified Autologous T Cell Immunotherapy Indicated For The Treatment Of Adult Patients With Relapsed Or Refractory Multiple Myeloma After Four Or More Prior Lines Of Therapy, Including An Immunomodulatory Agent, A Proteasome Inhibitor, And An Anti-Cd38 Monoclonal Antibody.

  • PRIVIGEN®, Immune Globulin Intravenous (Human), 10% Liquid


    CSL BEHRING LLC

    Privigen Is Indicated For The Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) In Adults. Limitation Of Use: Maintenance Therapy In Cidp Has Not Been Studied For Periods Longer Than 6 Months. Individualize Duration Of Treatment Beyond 6 Months Based On Patient Response.

  • BRUKINSA® (zanubrutinib) sponsored by Beigene, Ltd.


    BEIGENE USA, IN

    Brukinsa® (Zanubrutinib) Is A Kinase Inhibitor Indicated For The Treatment Of Adult Patients With: Waldenström’S Macroglobulinemia (Wm). Mantle Cell Lymphoma (Mcl) Who Have Received At Least One Prior Therapy. Relapsed Or Refractory Marginal Zone Lymphoma (Mzl) Who Have Received At Least One Anti-Cd20-Based Regimen.

  • Zepbound® (tirzepatide) Injection, sponsored by Lilly USA, LLC


    ELI LILLY & CO.

    Zepbound® Is Indicated As An Adjunct To A Reduced-Calorie Diet And Increased Physical Activity For Chronic Weight Management In Adults With An Initial Body Mass Index (Bmi) Of: 30 Kg/M2 Or Greater (Obesity) Or 27 Kg/M2 Or Greater (Overweight) In The Presence Of At Least One Weight-Related Comorbid Condition (E.G., Hypertension, Dyslipidemia, Type 2 Diabetes Mellitus, Obstructive Sleep Apnea, Or Cardiovascular Disease

  • ZERBAXA® (ceftolozane and tazobactam) is sponsored by Merck.


    MERCK SHARP & D

    Zerbaxa Is Indicated For The Treatment Of Adult Patients (18 Years And Older) With Hospital-Acquired Bacterial Pneumonia And Ventilator-Associated Bacterial Pneumonia (Habp/Vabp), Caused By The Following Susceptible Gram-Negative Microorganisms: Enterobacter Cloacae, Escherichia Coli, Haemophilus Influenzae, Klebsiella Oxytoca, Klebsiella Pneumoniae, Proteus Mirabilis, Pseudomonas Aeruginosa, And Serratia Marcescens. Zerbaxa Is Indicated For The Treatment Of Adult And Pediatric Patients (B

  • KEYTRUDA® (pembrolizumab) is sponsored by Merck.


    MERCK SHARP & D

    Adjuvant Therapy For Melanoma Keytruda Is Indicated For The Adjuvant Treatment Of Adult And Pediatric (12 Years And Older) Patients With Stage Iib, Iic, Or Iii Melanoma Following Complete Resection. Adjuvant Treatment For Renal Cell Carcinoma (Rcc) Keytruda Is Indicated For The Adjuvant Treatment Of Patients With Renal Cell Carcinoma (Rcc) At Intermediate-High Or High Risk Of Recurrence Following Nephrectomy, Or Following Nephrectomy And Resection Of Metastatic Lesions.

  • Jakafi® (ruxolitinib) - Incyte Corporation


    Incyte Corporation

    Jakafi Is Indicated For Treatment Of Intermediate Or High-Risk Myelofibrosis, Including Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis And Post-Essential Thrombocythemia Myelofibrosis In Adults, And, Polycythemia Vera In Adults Who Have Had An Inadequate Response To Or Are Intolerant Of Hydroxyurea, And Steroid-Refractory Acute Graft-Versus-Host Disease In Adult And Pediatric Patients 12 Years And Older.

  • LEQEMBI® (lecanemab-irmb) sponsored by Eisai Inc. and Biogen.


    EISAI INC.

    Leqembi Is Indicated For The Treatment Of Alzheimer’S Disease. Treatment With Leqembi Should Be Initiated In Patients With Mild Cognitive Impairment Or Mild Dementia Stage Of Disease, The Population In Which Treatment Was Initiated In Clinical Trials.